Financings in Brief: Lifecore Biomedical
This article was originally published in The Gray Sheet
Lifecore Biomedical: Firm's board of directors adopts shareholder rights plan, intended to "ensure that all of the company's shareholders receive fair and equal treatment in the event of any proposal to acquire the company." Distribution of rights, which become exercisable "following the acquisition by a person or group, without the prior consent of the Lifecore Board, of 15 percent or more of the company's voting stock, or following the announcement of a tender offer or exchange offer to acquire an interest of 15 percent or more"...
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.